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Abstract: The objective of this study was to
compare the anti-inflammatory effects of NG
-nitro L-arginine (L-NAME) and corticosteroid
in Concanavalin A-induced uveitis in rats.
Sixteen male Wistar rats were used. After
general anesthesia, intravitreal 0.1 ml
Concanavalin A (100µg/ml) was injected into
the left eyes of the rats. The animals were
divided into 3 groups: group 1 (6 animals)
received intraperitoneal 0.2 ml L-NAME (200
mg/kg) 1 hour before, 1 day and 3 days after
Concanavalin A injection, group 2 (6 animals)
received tropical 1% prednisolone acetate
four times a day for 3 weeks, group 3 (4
animals) received an intraperitoneal injection
of 0.2 ml balanced salt solution (BSS) 1 hour
before, 1 day and 3 days after Concanavalin
A injection, as a control group. Anterior and
posterior inflammations were observed with
a slit lamp. Three weeks after the last
injection, all eyes treated with L-NAME and
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Introduction
Uveitis is a chronic inflammatory condition of the eye
involving both anterior and posterior segment. It remains
a major cause of significant visual loss worldwide(1). One
of the main sight-threatening complications is macular
edema which often causes deep loss of central vision and
may or may not respond to conventional therapies.
Any immunologic or inflammatory stimuli induce the
production of nitric oxide (NO) by the expression of the
inducible isoform of the nitric oxide synthase (NOS) (2).
It is well known that NO is involved in different kinds of
inflammatory conditions such as arthritis, colitis and
nephritis (3–5). Concanavalin A is a nonspecific
inflammatory agent, which has been used in many
previous experimental studies to induce uveitis (6–8).
Current management of uveitis consists of suppressing

topical steroid showed significantly reduced
anterior chamber inflammation, while eyes
which received BSS showed moderate to
severe inflammation in both anterior and
posterior segments. Both drugs showed no
real effect on the vitreous humor at the end
of follow up period. In conclusion, our feeling
is that tropical steroid appears to still be the
mainstay therapy for the treatment of
anterior uveitis, but nitric oxide synthase
(NOS) inhibition might be an alternative to
steroids as a second line drug, at least
whenever there are any adverse reactions or
contraindications to corticosteroid drugs. LNAME might also be effective on vitreous
inflammation with new application methods
and concentrations.

Key Words: Concanavalin A, L-NAME,
Steroid, Uveitis.

the immune system to reduce the inflammatory response,
using either local or systemic drugs (9). Corticosteroids
still remain the major choice for uveitis treatment, which
also reduce the induction of NOS in many organs
(10–11). Another drug used in this study was L-NAME,
an inhibitor of NOS, reduces the inflammation in the eye
(12).
We compared the anti-inflammatory effects of LNAME and corticosteroid as a first in Concanavalin Ainduced inflammation.
Materials and Methods
Sixteen male Wistar rats (6 to 8 weeks of age, 150 to
200 g) were used. The animals were handled and cared
for according to the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research. The rats were
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anesthetized with intraperitoneal injection of 50 mg/kg
ketamine HCI and 10 mg/kg xylazine. Corneal anesthesia
was achieved with topical 0.4% oxbuprocaine HCL.
All injections of Concanavalin A (100 mg/ml, Sigma,
St. Louis, MO) were only in the left eyes of the rats, using
a 30-gauge needle. After that the rats were divided into
3 groups. Group 1 was treated with a 0.2 ml
intraperitoneal injection of L-NAME (200mg/kg, Sigma) 1
hour before, 1 day and 3 days after Concanavalin A
injection. Group 2 was treated with topical 1%
prednisolone acetate (Pred Forte, Allergan) four times a
day for 3 weeks. Group 3 received an intraperitoneal
injection of equal volume of BSS at the same times with
L-NAME injections. Postoperatively, all ayes received 1%
cyclopentolate 2 times daily for 2 weeks to maintain
dilation. All eyes were examined with slit lamp
biomicroscopy findings were graded on a scale from 0 to
4 with 0=none, 1=trace, 2=mild, 3=moderate, and
4=severe (Table 1). The Wilcoxon Rank test was used for
intergroup comparisons.
Table 1.

Inflammation Grading Scale.

Cells

None
Trace
Mild
Moderate
Severe

Grade

Description

0
1
2
3
4

No cells seen per high power field
1-9 cells seen per high power field
10-25 cells seen per high power field
26-50 cells seen per high power field
More than 50 cells seen per high power field

Results
Our results are shown in Tables 2 and 3. On day 3, all
eyes in group 1 and 2 showed none to trace cells both in
the anterior chamber and in the vitreous humor. Group 3

Day

3
7
15
18
21

Group 1

0.84
0.66
0.31
0.16
0.0

±
±
±
±

0.17
0.15
0.21
0.18

Group 2

0.75 ± 0.14
0.59 ± 0.21
0.25 ± 0.19
0.0
0.0

Control

1.81
2.06
2.44
2.61
3.04

±
±
±
±
±

0.32
0.13
0.28
0.17
0.24

eyes showed trace cells, and none to trace cells in the
anterior and posterior segments, respectively.
Anterior segment inflammation gradually subsided
after between 7 and 15 days in groups 1 and 2, while
posterior segment inflammation increased with mild cells.
There was evidence of inflammation in all BSS-treated
eyes with mild cells in the anterior chamber and moderate
inflammation in the vitreous humor on these days.
The anterior segments were normal in steroid and LNAME-treated groups on the 18th and 21st day after
Concanavalin A injection, respectively. However, on the
21st day, either anterior or posterior segment
inflammations were at moderate levels in the control
group. The posterior segment iflammation peaked on the
21st day, then started to gradually decrease from day 21
to 45 in all groups. No significant differences were
observed betweet groups 1 and 2 in either segment at
any time (p>0.05). The differences were statistically
significant between the-treatment groups and the control
group in the anterior segment inflammation (p=0.001 to
0.04). However, the difference was statistically significant
only on days 21, 35, and 45 in the posterior segment
(p=0.02 to 0.04). After 45 days, it was difficult to
evaluate vitreous inflammation due to the development of
cataracts.
Discussion
The spectrum of uveitis constitutes one of the major
causes of blindness. Uveitis is an iflammation of the iris,
ciliary body or choroid. It is not a specific disease, and it
can be caused by a multitude of conditions, including
antigen specific immune mediated inflammation,
infection, trauma, and surgery (13). The inflammatory
response in the eye consists of miosis, conjunctival
hyperemia and breakdown of the blood-aqueous barrier
with subsequent leakage of protein into the aqueous
humor.
P Value
(Between groups
1,2 and control)
0.040
0.028
0.005
0.002
0.001

Values are mean ± SE. Bİomicroscopy findings are graded on a scale from 0 to 4; 0=none, 1=
trace, 2=mild, 3=moderate,, and 4=severe.
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Table 2.

Anterior
Chamber
Ocular Inflammation at
Different Time Intervals.
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The animal model of experimental Concanavalin A
uveitis has been widely used for immunogenic studies and
has been shown to induce uveitis after intravitreal
injection(6-8). It is a nonspecific inflammatory agent and
mitogen for T cells and some B cells.

play a crucial role in the inflammatory process and
express high affinity receptors for corticosteroids (23).
The inhibition of induction of the inducible NOS in
macrophages by corticosteroids is possibly mediated via
interaction with specific receptors.

New therapeutic approaches and drugs such as
cyclosporin A, azothioprine, cyclophosphamide,
indomethacin are being used and hyperemia also assessed
as second line therapies, especially when steroids alone
are not effective or too high a dose in required to achieve
the desired effects (14,15). Corticosteroids have both
immunosuppressive and anti-inflammatory actions
(16,17). Part of the these actions is due to inhibition of
the induction of the NOS (18). NO is generated from Larginine by the enzyme NOS, which is inhibited effectively
either in vitro or in vivo, by analogues of L-NAME (19).
Two types of NOS have been identified, one constitutive
and Ca2+-dependent and the other inducible and Ca2+independent (19). The inducible form is found in many
types of cells, such as macrophages, neutrophils,
endothelial cells, vascular smooth muscles, and retinal
pigment epithelial cells (20,21). NOS activity has been
measured in the anterior uvea of the rabbit (22).
Intraperitoneal injections of L-NAME were shown to
reduce the formation of nitric oxide and prevent the
clinical, histological signs of uveitis (12). Macrophages

In summary, we compared L-NAME and corticosteroid
for the first time in experimental Concanavalin A-induced
uveitis. Our data shows that intraperitoneal L-NAME is as
effective as topical steroid in reducing anterior chamber
inflammation, but needs further investigation to find
more suitable application routes such as topical. In the
posterior segment inflammation, neither drug appeared
to be effective. On the other hand, our feeling is that
intravitreal
L-NAME
application
at
different
concentrations might be more effective in the treatment
of vitreous inflammation. Finally, this study demonstrates
the therapeutic potential of NOS inhibition for the
treatment of anterior uveitis, especially whenever any
adverse reactions to corticosteroid eye drops are
suspected or occur.
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Table 3.

Day

3
7
15
18
21
35
45

Group 1

0.18
1.83
2.32
2.41
2.60
2.13
1.48

±
±
±
±
±
±
±

0.16
0.30
0.18
0.33
0.29
0.19
0.18

Group 2

0.16
1.94
2.35
2.39
2.67
2.20
1.65

±
±
±
±
±
±
±

Control

0.14
0.25
0.22
0.24
0.19
0.23
0.31

0.71
2.74
3.08
3.14
3.82
3.52
2.60

±
±
±
±
±
±
±

0.20
0.21
0.16
0.16
0.33
0.15
0.17

Posterior
Chamber
Ocular Inflammation at
Different Time Intervals.

P Value
(Between groups
1,2 and control)
0.083
0.064
0.072
0.072
0.033
0.023
0.046

Values are mean ± SE. Biomicroscopy findings are graded on a scale from 0 to 4; 0=none, 1=
trace, 2=mild, 3=moderate, and 4= severe.
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